Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

@article{Wong2010DurabilityOP,
  title={Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.},
  author={Vincent Wai-Sun Wong and Grace Lai-Hung Wong and K. K. Yan and Angel Mei-ling Chim and Henry Lik-Yuen Chan and Chi-Hang Tse and Paul Cheung-lung Choi and Anthony Wing-Hung Chan and Joseph J. Y. Sung and Henry L. Y. Chan},
  journal={Hepatology},
  year={2010},
  volume={51 6},
  pages={1945-53}
}
UNLABELLED Approximately 30%-40% of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B treated with peginterferon and/or lamivudine achieve HBeAg seroconversion 6 months after the end of treatment. The durability and long-term effect of treatment are unknown. In this study, 85 HBeAg-positive patients who received peginterferon alfa-2b 1.5 microg/kg/week for 32 weeks and lamivudine 100 mg/day for 52 or 104 weeks were prospectively followed for 6.1 +/- 1.7 years… CONTINUE READING
29 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Similar Papers

Loading similar papers…